Identifying patients at high risk for nausea and vomiting after chemotherapy: The development of a practical validated prediction tool: II. Delayed nausea and vomiting

Journal of Supportive Oncology

Volumn 7, Issue 4, 2009, Pages

  Petrella, Teresa ^a,b,c   Clemons, Mark ^a,b,c   Joy, Anil ^a,b,c   Young, Scott ^a,b,c   Callaghan, Walter ^a,b,c   Dranitsaris, George ^a,b,c  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

^c Northeastern Ontario Regional Cancer Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIEMETIC AGENT; DEXAMETHASONE; GRANISETRON; ONDANSETRON; PLATINUM COMPLEX;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; FEMALE; GYNECOLOGIC CANCER; HIGH RISK PATIENT; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MORNING SICKNESS; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PREDICTION; PREGNANCY; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; UROGENITAL TRACT CANCER; VALIDATION PROCESS;

EID: 70349240809     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. de Boer-Dennert M, de Wit R, Schmitz PI, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 1997;76:1055-1061.
2. Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 2005;13:219-227.
3. Rusthoven JJ, Osoba D, Butts CA, Yelle L, Findlay H, Grenville A. The impact of postchemotherapy nausea and vomiting on quality of life after moderately emetogenic chemotherapy. Support Care Cancer 1998;6:389-395.
4. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112-4119.
5. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. The Italian Group for Antiemetic Research. N Engl J Med 2000;342:1554-1559.
6. Herrstedt J, Muss HB, Warr DG, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005;104:1548-1555.
7. Fabi A, Barduagni M, Lauro S, et al. Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? an observational study. Support Care Cancer 2003;11:156-161.
8. Jordan K, Kasper C, Schmoll HJ. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer 2005;41:199-205.
9. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004;100:2261-2268.
10. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-2830.
11. Tsavaris N, Kosmas C, Mylonakis N, et al. Parameters that influence the outcome of nausea and emesis in cisplatin based chemotherapy. Anticancer Res 2000;20:4777-4783.
12. Roila F, Donati D, Tamberi S, Margutti G. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 2002;10:88-95.
13. Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients? The Italian Group for Antiemetic Research. Ann Oncol 1997;8:561-567.
14. Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L. Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997;15:116-123.
15. Molassiotis A, Yam BM, Yung H, Chan FY, Mok TS. Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Support Care Cancer 2002;10:139-145.
16. Roila F, Boschetti E, Tonato M, et al. Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone: a randomized single-blind study. Am J Clin Oncol 1991;14:238-242.
17. Allison PD. Logistic Regression Using the SAS System: Theory and Application. Cary, NC: SAS Institute Inc; 1999:179-216.
18. Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001;54:774-781.
19. Steyerberg EW, Eijkemans MJ, Harrell FE Jr, Habbema JD. Prognostic modeling with logistic regression: in search of a sensible strategy in small data sets. Med Decis Making 2001;21:45-56.
20. McNeil BJ, Hanley JA. Statistical approaches to the analysis of receiver operating characteristic (ROC) curves. Med Decis Making 1984;4:137-150.
21. Krupp NL, Weinstein G, Chalian A, Berlin JA, Wolf P, Weber RS. Validation of a transfusion prediction model in head and neck surgery. Arch Otolaryngol Head Neck Surg 2003;129:1297-1302.
22. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite anti-emetic treatment. J Clin Oncol 2006;24:4472-4478.
23. Dranitsaris G, Clemons M, Verma S, Lau C, Vincent M. Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: development of a prediction model. Lancet Oncol 2005;6:856-863.
24. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 1999;4:191-196.
25. Moore S, Tumeh J, Wojtanowski S, Flowers C. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Value Health 2007;10:23-31.